Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · see citing works

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198 · see citing works

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers

Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634 · see citing works

Olaparib for Metastatic Breast Cancer in Patients with a Germline <i>BRCA</i> Mutation

Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294 · see citing works

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Pujade-Lauraine, É., Ledermann, J. A., Selle, F., Gebski, V., Penson, R. T., Oza, A. M., Korach, J., Huzarski, T., Poveda, A. M., Pignata, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30469-2 · Cited by 1,856 · see citing works

XRCC3 promotes homology-directed repair of DNA damage in mammalian cellsPreprint

Pierce, A. J., Johnson, R. D., Thompson, L. H., & Jasin, M. (1999) · Genes & Development · doi:10.1101/gad.13.20.2633 · Cited by 1,384 · see citing works

Combenefit: an interactive platform for the analysis and visualization of drug combinations

Veroli, G. Y. D., Fornari, C., Wang, D. Y. Q., Mollard, S., Bramhall, J. L., Richards, F. M., & Jodrell, D. I. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw230 · Cited by 736 · see citing works

AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer

Wedge, S. R., Kendrew, J., Hennequin, L. F., Valentine, P. J., Barry, S. T., Brave, S. R., Smith, N. R., James, N. H., Dukes, M., Curwen, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4409 · Cited by 720 · see citing works

Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation

Chen, J., Martin, B. L., & Brautigan, D. L. (1992) · Science · doi:10.1126/science.1325671 · Cited by 601 · see citing works

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

Liu, J. F., Barry, W. T., Birrer, M. J., Lee, J.-M., Buckanovich, R. J., Fleming, G. F., Rimel, B. J., Buss, M. K., Nattam, S. R., Hurteau, J. A., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70391-2 · Cited by 583 · see citing works

2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity

Sulkowski, P. L., Corso, C. D., Robinson, N. D., Scanlon, S. E., Purshouse, K. R., Bai, H., Liu, Y., Sundaram, R. K., Hegan, D. C., Fons, N. R., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal2463 · Cited by 556 · see citing works

Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial

Clarke, N. W., Wiechno, P., Alekseev, B. Y., Sala, N., Jones, R., Kocák, I., Chiurì, V. E., Jassem, J., Fléchon, A., Redfern, C. H., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30365-6 · Cited by 397 · see citing works

Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition

Krawczyk, P. M., Eppink, B., Essers, J., Stap, J., Rodermond, H. M., Odijk, H., Zelensky, A. N., Chris van, B. R. E. E., Stalpers, L. J. A., Buist, M. R., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1101053108 · Cited by 353 · see citing works

Hypoxia-Induced Down-regulation of BRCA1 Expression by E2Fs

Bindra, R. S., Gibson, S. L., Meng, A. X., Westermark, U., Jasin, M., Pierce, A. J., Bristow, R. G., Classon, M. K., & Glazer, P. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2119 · Cited by 334 · see citing works

Chronic Hypoxia Decreases Synthesis of Homologous Recombination Proteins to Offset Chemoresistance and Radioresistance

Chan, N. H. L., Koritzinsky, M., Zhao, H. W., Bindra, R. S., Glazer, P. M., Powell, S. N., Belmaaza, A., Wouters, B. G., & Bristow, R. G. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5472 · Cited by 328 · see citing works

Functional Restoration of BRCA2 Protein by Secondary BRCA2 Mutations in BRCA2 -Mutated Ovarian Carcinoma

Sakai, W., Swisher, E. M., Jacquemont, C. F., Chandramohan, K. V., Couch, F. J., Langdon, S. P., Wurz, K., Higgins, J., Villegas, E., & Taniguchi, T. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1178 · Cited by 322 · see citing works

Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer

Li, L., Karanika, S., Yang, G., Wang, J., Park, S., Broom, B. M., Manyam, G. C., Wu, W., Luo, Y., Basourakos, S. P., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aam7479 · Cited by 294 · see citing works

Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor Microenvironment

Chan, N. H. L., Pires, I. M., Bencokova, Z., Coackley, C. L., Luoto, K. R., Bhogal, N., Lakshman, M., Gottipati, P., Oliver, F. J., Helleday, T., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2352 · Cited by 243 · see citing works

Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130

Hegan, D. C., Lü, Y., Stachelek, G. C., Crosby, M. E., Bindra, R. S., & Glazer, P. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904783107 · Cited by 209 · see citing works

Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.

Liu, J. F., Barry, W., Birrer, M., Lee, J., Buckanovich, R. J., Fleming, G., Rimel, B., Buss, M., Nattam, S., Hurteau, J. A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz018 · Cited by 165 · see citing works

Repression of RAD51 gene expression by E2F4/p130 complexes in hypoxia

Bindra, R. R., & Glazer, P. M. (2006) · Oncogene · doi:10.1038/sj.onc.1210001 · Cited by 162 · see citing works

Autophosphorylation-activated protein kinase phosphorylates and inactivates protein phosphatase 2A.

Guo, H., & Damuni, Z. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.6.2500 · Cited by 161 · see citing works

Hypoxia-Induced Epigenetic Regulation and Silencing of the BRCA1 Promoter

Lu, Y.-H., Chu, A., Turker, M., & Glazer, P. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.01121-10 · Cited by 141 · see citing works

Oxidative Stress Induces Protein Phosphatase 2A-dependent Dephosphorylation of the Pocket Proteins pRb, p107, and p130

Cicchillitti, L., Fasanaro, P., Biglioli, P., Capogrossi, M. C., & Martelli, F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300511200 · Cited by 129 · see citing works

The mTOR and PP2A pathways regulate PHD2 phosphorylation to fine-tune HIF1α levels and colorectal cancer cell survival under hypoxia

Di Conza, G., Trusso Cafarello, S., Loroch, S., Mennerich, D., Deschoemaeker, S., Di Matteo, M., Ehling, M., Gevaert, K., Prenen, H., Zahedi, R. P., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.01.051 · Cited by 119 · see citing works

Development of an assay to measure mutagenic non-homologous end-joining repair activity in mammalian cells

Bindra, R. S., Goglia, A. G., Jasin, M., & Powell, S. N. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt255 · Cited by 88 · see citing works

Isolation and initial characterization of the BRCA2 promoter

Davis, P. L., Miron, A., Andersen, L. M., Iglehart, J. D., & Marks, J. R. (1999) · Oncogene · doi:10.1038/sj.onc.1202990 · Cited by 60 · see citing works

Characterization of Cardiac Glycoside Natural Products as Potent Inhibitors of DNA Double-Strand Break Repair by a Whole-Cell Double Immunofluorescence Assay

Surovtseva, Y. V., Jairam, V., Salem, A. F., Sundaram, R. K., Bindra, R. S., & Herzon, S. B. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b00162 · Cited by 58 · see citing works

Hypoxic Stress Facilitates Acute Activation and Chronic Downregulation of Fanconi Anemia Proteins

Scanlon, S. E., & Glazer, P. M. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0628 · Cited by 45 · see citing works

The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials

Guo, X. X., Wu, H., Shi, H., Su, L., & Zhang, X. (2018) · Cancer Management and Research · doi:10.2147/cmar.s169558 · Cited by 44 · see citing works

Protein Phosphatase 2A Associates with Rb2/p130 and Mediates Retinoic Acid-induced Growth Suppression of Ovarian Carcinoma Cells

Vuocolo, S. C., Purev, E., Zhang, D., Bártek, J., Hansen, K. H., Soprano, D. R., & Soprano, K. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302715200 · Cited by 43 · see citing works

Intermittent hypoxia-induced protein phosphatase 2A activation reduces PC12 cell proliferation and differentiation

Chen, T.-I., Chiu, H.-W., Pan, Y., Hsu, S.-T., Lin, J., & Yang, K. (2014) · Journal of Biomedical Science · doi:10.1186/1423-0127-21-46 · Cited by 29 · see citing works

Acute vascular response to cediranib treatment in human non-small-cell lung cancer xenografts with different tumour stromal architecture

Jiang, Y., Allen, P. D., Kersemans, V., Devery, A., Bokobza, S., Smart, S., & Ryan, A. J. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.08.009 · Cited by 15 · see citing works

18F-Fluoromisonidazole Kinetic Modeling for Characterization of Tumor Perfusion and Hypoxia in Response to Antiangiogenic Therapy

Grkovski, M., Emmas, S.-A., & Carlin, S. D. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.190892 · Cited by 14 · see citing works

Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance

Wu, W. E., Klockow, J., Zhang, M., Lafortune, F., Chang, E., Jin, L., Wu, Y., & Daldrup-Link, H. E. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105780 · Cited by 833 · see citing works

Therapeutic targeting of the hypoxic tumour microenvironment

Singleton, D. C., Macann, A., & Wilson, W. R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00539-4 · Cited by 493 · see citing works

Anti-angiogenic therapy: current challenges and future perspectives

Lopes-Coelho, F., Martins, F., Pereira, S. A., & Serpa, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073765 · Cited by 416 · see citing works

Glioblastoma Therapy: Past, Present and Future

Obrador, E., Moreno-Murciano, P., Oriol‐Caballo, M., López‐Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Bonet, L. G. G., Martínez‐Cadenas, C., Estrela, J. M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 263 · see citing works

Functions and mechanisms of circular RNAs in cancer radiotherapy and chemotherapy resistance

Cui, C., Yang, J., Xiao, L., Liu, D., Fu, L., & Wang, X. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01180-y · Cited by 204 · see citing works

Harnessing DNA Double-Strand Break Repair for Cancer Treatment

Trenner, A., & Sartori, A. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01388 · Cited by 190 · see citing works

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer

McMullen, M., Karakasis, K., Madariaga, A., & Oza, A. M. (2020) · Cancers · doi:10.3390/cancers12061607 · Cited by 194 · see citing works

PARP inhibitors: enhancing efficacy through rational combinations

Bhamidipati, D., Haro-Silerio, J. I., Yap, T. A., & Ngoi, N. Y. L. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02326-7 · Cited by 179 · see citing works

Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence

Wang, Q., Peng, H., Qi, X., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0199-6 · Cited by 157 · see citing works

The systemic treatment of recurrent ovarian cancer revisited

Baert, T., Ferrero, A., Sehouli, J., O’Donnell, D. M., González-Martı́n, A., Joly, F., van der Velden, J., Blecharz, P., Tan, D. S. P., Querleu, D., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.02.015 · Cited by 153 · see citing works

EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression

Lheureux, S., Oaknin, A., Garg, S., Bruce, J. P., Madariaga, A., Dhani, N. C., Bowering, V. L., White, J., Accardi, S., Tan, D. S. P., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4121 · Cited by 132 · see citing works

Hypoxia signaling in cancer: Implications for therapeutic interventions

Zhuang, Y., Liu, K., He, Q., Gu, X., Jiang, C., & Wu, J. (2023) · MedComm · doi:10.1002/mco2.203 · Cited by 119 · see citing works

Development of synthetic lethality in cancer: molecular and cellular classification

Li, S., Topatana, W., Juengpanich, S., Cao, J., Hu, J., Zhang, B., Ma, D., Cai, X., & Chen, M. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00358-6 · Cited by 117 · see citing works

Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer

Chiappa, M., Guffanti, F., Bertoni, F., Colombo, I., & Damia, G. L. M. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100744 · Cited by 112 · see citing works

Endometrial cancer: molecular classification and future treatments

Corr, B. R., Cosgrove, C. M., Spinosa, D., & Guntupalli, S. R. (2022) · BMJ Medicine · doi:10.1136/bmjmed-2022-000152 · Cited by 105 · see citing works

Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial

Liu, J. F., Brady, M. F., Matulonis, U. A., Miller, A., Kohn, E. C., Swisher, E. M., Cella, D. F., Tew, W. P., Cloven, N. G., Muller, C. Y., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02011 · Cited by 99 · see citing works

Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms

Jain, A., Barge, A., & Parris, C. N. (2024) · Oncogene · doi:10.1038/s41388-024-03227-6 · Cited by 100 · see citing works

New approaches for targeting platinum-resistant ovarian cancer

McMullen, M., Madariaga, A., & Lheureux, S. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.08.013 · Cited by 88 · see citing works

Impact of hypoxia on DNA repair and genome integrity

Kaplan, A. R., & Glazer, P. M. (2019) · Mutagenesis · doi:10.1093/mutage/gez019 · Cited by 87 · see citing works

PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies

Lee, E. K., & Matulonis, U. A. (2020) · Cancers · doi:10.3390/cancers12082054 · Cited by 74 · see citing works

Nanoparticles in precision medicine for ovarian cancer: From chemotherapy to immunotherapy

Li, Y., Gao, Y., Zhang, X., Guo, H., & Gao, H. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119986 · Cited by 68 · see citing works

First-Line Management of Advanced High-Grade Serous Ovarian Cancer

Mahmood, R. D., Morgan, R. D., Edmondson, R. J., Clamp, A. R., & Jayson, G. C. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00933-8 · Cited by 68 · see citing works

Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options

Garg, V., & Oza, A. M. (2023) · Drugs · doi:10.1007/s40265-023-01934-0 · Cited by 69 · see citing works

Recent advancements of antiangiogenic combination therapies in ovarian cancer

An, D., Banerjee, S. N., & Lee, J. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102224 · Cited by 66 · see citing works

Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer

Colombo, N., Tomao, F., Panici, P. B., Nicoletto, M. O., Tognon, G., Bologna, A., Lissoni, A. A., DeCensi, A., Lapresa, M., Mancari, R., et al. (2022) · Gynecologic Oncology · doi:10.1016/j.ygyno.2022.01.015 · Cited by 65 · see citing works

Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations

Veneris, J. T., Matulonis, U. A., Liu, J. F., & Konstantinopoulos, P. A. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.09.021 · Cited by 62 · see citing works

VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status

Bizzaro, F., Nerini, I. F., Taylor, M. A., Anastasia, A., Russo, M., Damia, G. L. M., Guffanti, F., Guana, F., Ostano, P., Minoli, L., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01196-x · Cited by 62 · see citing works

Hypoxia-Mediated Decrease of Ovarian Cancer Cells Reaction to Treatment: Significance for Chemo- and Immunotherapies

Klemba, A., Bodnar, L., Waś, H., Brodaczewska, K. K., Wcisło, G., Szczylik, C. A., & Kiéda, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249492 · Cited by 59 · see citing works

Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial

Lee, J., Moore, R. G., Ghamande, S. A., Park, M. S., Diaz, J. P., Chapman, J. A., Kendrick, J. E., Slomovitz, B. M., Tewari, K. S., Lowe, E., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1733 · Cited by 53 · see citing works

Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer

Zhu, Q., Dai, Q., Zhao, L., Zheng, C., Li, Q., Yuan, Z., Li, L., Xie, Z., Qiu, Z., Huang, W., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-023-06303-z · Cited by 55 · see citing works

Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984

Kim, J. W., McKay, R. R., Radke, M. R., Zhao, S., Taplin, M., Davis, N. B., Monk, P., Appleman, L. J., Lara, P. N., Vaishampayan, U. N., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02947 · Cited by 48 · see citing works

Genomic profiling of platinum-resistant ovarian cancer: The road into druggable targets

da Costa, A. A. B. A., & Baiocchi, G. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.10.016 · Cited by 48 · see citing works

Targeting DNA damage repair pathways in pancreas cancer

Crowley, F., Park, W., & O’Reilly, E. M. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09983-1 · Cited by 43 · see citing works

Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1/2 and RAD51

Tao, L., Zhou, Y., Pan, X., Luo, Y., Qiu, J., Zhou, X., Chen, Z., Li, Y., Xu, L., Zhou, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42850-x · Cited by 43 · see citing works

Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy

Gou, R., Dong, H., & Lin, B. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118434 · Cited by 40 · see citing works

Targeted therapies in gynaecological cancers

Crusz, S. M., & Miller, R. E. (2019) · Histopathology · doi:10.1111/his.14009 · Cited by 37 · see citing works

Antiangiogenic Strategies in Epithelial Ovarian Cancer: Mechanism, Resistance, and Combination Therapy

Jin, C., Yuan, M., Bu, H., & Jin, C. (2022) · Journal of Oncology · doi:10.1155/2022/4880355 · Cited by 37 · see citing works

Ovarian cancer: new strategies and emerging targets for the treatment of patients with advanced disease

Arend, R. C., Jackson-Fisher, A. J., Jacobs, I. A., Chou, J., & Monk, B. J. (2021) · Cancer Biology & Therapy · doi:10.1080/15384047.2020.1868937 · Cited by 35 · see citing works

PARP inhibitors for prostate cancer

Longoria, O., Beije, N., & de Bono, J. S. (2024) · Seminars in Oncology · doi:10.1053/j.seminoncol.2023.09.003 · Cited by 34 · see citing works

Systematic Characterization of Recurrent Genomic Alterations in Cyclin-Dependent Kinases Reveals Potential Therapeutic Strategies for Cancer Treatment

Shan, W., Yuan, J., Hu, Z., Jiang, J., Wang, Y., Loo, N., Fan, L., Tang, Z., Zhang, T., Xu, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107884 · Cited by 34 · see citing works

Glycogen synthase kinase 3β inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancer

Zhang, N., Tian, Y., Zhou, L., Li, M., Chen, H., Song, S., Huan, X., Bao, X., Zhang, A., Miao, Z., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03475-4 · Cited by 33 · see citing works

Ovarian cancer targeted therapy: current landscape and future challenges

Wang, G., Yang, H., Wang, Y., & Qin, J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1535235 · Cited by 32 · see citing works

ICON 9—an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy

Elyashiv, O., Ledermann, J. A., Parmar, G., Farrelly, L., Counsell, N., Feeney, A., El-Khouly, F., Macdonald, I. A., Neto, A., Arthur-Darkwa, E., et al. (2020) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2020-002073 · Cited by 32 · see citing works

PARP inhibitor combinations in prostate cancer

Pezaro, C. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919897537 · Cited by 32 · see citing works

Discovery, Synthesis, and Evaluation of Novel Dual Inhibitors of a Vascular Endothelial Growth Factor Receptor and Poly(ADP-Ribose) Polymerase for BRCA Wild-Type Breast Cancer Therapy

Li, Y., Liu, Y., Zhang, D., Chen, J., Yang, G., Tang, P., Yang, C., Liu, J., Zhang, J., & Ouyang, L. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00640 · Cited by 31 · see citing works

Evaluation of the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis

Wu, K., Liang, J., Shao, Y., Xiong, S.-C., Feng, S., & Li, X. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.777663 · Cited by 31 · see citing works

Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer

Flynn, M. J., & Ledermann, J. A. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.13 · Cited by 30 · see citing works

Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial

Ledermann, J. A., Embleton-Thirsk, A., Perren, T. J., Jayson, G. C., Rustin, G. J. S., Kaye, S. B., Hirte, H. W., Oza, A. M., Vaughan, M. M., Friedlander, M. L., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100043 · Cited by 28 · see citing works

Combination Treatment Strategies to Overcome PARP Inhibitor Resistance

Soung, Y. H., & Chung, J. (2023) · Biomolecules · doi:10.3390/biom13101480 · Cited by 27 · see citing works

Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer

Nicum, S., McGregor, N., Austin, R., Collins, L., Dutton, S., McNeish, I. A., Glasspool, R. M., Hall, M., Roux, R. L., Michael, A., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-023-02567-6 · Cited by 26 · see citing works

Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005

Lee, J., Brady, M. F., Miller, A., Moore, R. G., MacKay, H. J., McNally, L. J., Lea, J. S., Street, D. G., Lheureux, S., McDonald, M. E., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00683 · Cited by 26 · see citing works

Targeting RECQL5 Functions, by a Small Molecule, Selectively Kills Breast Cancer in Vitro and in Vivo

Chakraborty, S., Dutta, K., Gupta, P., Das, A. D., Das, A., Ghosh, S. K., & Patro, B. S. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01692 · Cited by 26 · see citing works

BBIT20 inhibits homologous DNA repair with disruption of the BRCA1–BARD1 interaction in breast and ovarian cancer

Raimundo, L., Paterna, A., Calheiros, J., Ribeiro, J., Cardoso, D., Piga, I., Junqueira-Neto, S., Hegan, D. C., Glazer, P. M., Indraccolo, S., et al. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15506 · Cited by 26 · see citing works

Pancreatic Cancer: BRCA Targeted Therapy and Beyond

Keane, F., O'Connor, C. A., Park, W., Seufferlein, T. T. W., & O'Reilly, E. M. (2023) · Cancers · doi:10.3390/cancers15112955 · Cited by 25 · see citing works

Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma

Kanakkanthara, A., Hou, X., Ekstrom, T. L., Zanfagnin, V., Huehls, A. M., Kelly, R. L., Ding, H., Larson, M. C., Vasmatzis, G., Oberg, A. L., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0732 · Cited by 23 · see citing works

Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer

Huang, X., Li, X., Shan, W., Chen, Y., Zhu, Q., & Xia, B.-R. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1131342 · Cited by 23 · see citing works

PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer

Flippot, R., Patrikidou, A., Aldea, M. D., Colomba, É., Lavaud, P., Albiges, L. K., Naoun, N., Blanchard, P., Terlizzi, M., Garcia, C., et al. (2022) · Drugs · doi:10.1007/s40265-022-01703-5 · Cited by 22 · see citing works

Poly( ADP ‐ribose) polymerase inhibition in pancreatic cancer

Singh, H. M., Bailey, P. J., Hübschmann, D., Berger, A. K., Neoptolemos, J. P., Jäger, D., Siveke, J. T., & Springfeld, C. (2020) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22932 · Cited by 22 · see citing works

A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial

Park, J., Lim, M. C., Lee, J. K., Jeong, D. H., Kim, S. I., Choi, M. C., Kim, B., & Lee, J. (2021) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2022.33.e12 · Cited by 21 · see citing works

PARP inhibition in treatment of pancreatic cancer

Hammel, P. R., Zhang, C., Matile, J., Colle, E., Hadj-Naceur, I., Gagaille, M.-P., Bouattour, M., Cros, J. F., de Mestier, L., & Lamuraglia, M. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1820330 · Cited by 19 · see citing works

NRG‐GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer

Rimel, B. J., Enserro, D. M., Bender, D., Jackson, C. G., Tan, A., Alluri, N., Borowsky, M. E., Moroney, J. W., Hendrickson, A. W., Backes, F. J., et al. (2023) · Cancer · doi:10.1002/cncr.35151 · Cited by 20 · see citing works

Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol

Mansouri, A., McGregor, N., Dunn, R., Dobbie, S. T., Holmes, J., Collins, L., & Nicum, S. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-041463 · Cited by 18 · see citing works

New hopes and promises in the treatment of ovarian cancer focusing on targeted treatment—a narrative review

Satora, M., Kułak, K., Zaremba, B., Grunwald, A., Świechowska-Starek, P., & Tarkowski, R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1416555 · Cited by 18 · see citing works

Individualization in the first-line treatment of advanced ovarian cancer based on the mechanism of action of molecularly targeted drugs

Nakai, H., & Matsumura, N. (2022) · International Journal of Clinical Oncology · doi:10.1007/s10147-022-02163-3 · Cited by 17 · see citing works

Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation

Kim, J. W., Cardin, D. B., Vaishampayan, U. N., Kato, S., Grossman, S. R., Glazer, P. M., Shyr, Y., Ivy, S. P., & LoRusso, P. M. (2021) · The Oncologist · doi:10.1002/onco.13758 · Cited by 17 · see citing works

Small Molecule Inhibitors Targeting Key Proteins in the DNA Damage Response for Cancer Therapy

Li, L., Kumar, A. K., Hu, Z., & Guo, Z. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200224102309 · Cited by 16 · see citing works

Vulnerability of IDH1-Mutant Cancers to Histone Deacetylase Inhibition via Orthogonal Suppression of DNA Repair

Dow, J., Krysztofiak, A., Liu, Y., Colón-Ríos, D. A., Rogers, F. A., & Glazer, P. M. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0456 · Cited by 16 · see citing works

Therapeutic Application of PARP Inhibitors in Neuro-Oncology

Ning, J., & Wakimoto, H. (2020) · Trends in cancer · doi:10.1016/j.trecan.2019.12.004 · Cited by 16 · see citing works

Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors

Lee, E. K., & Matulonis, U. A. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1773791 · Cited by 16 · see citing works

Resistance to Poly (ADP-Ribose) Polymerase Inhibitors (PARPi): Mechanisms and Potential to Reverse

Washington, C. R., & Moore, K. N. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01337-6 · Cited by 15 · see citing works

PG545 sensitizes ovarian cancer cells to PARP inhibitors through modulation of RAD51-DEK interaction

Ray, U., Thirusangu, P., Jin, L., Xiao, Y., Pathoulas, C. L., Staub, J. K., Erskine, C. L., Dredge, K. S., Hammond, E., Block, M. S., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02785-5 · Cited by 15 · see citing works

Bevacizumab increases the sensitivity of olaparib to homologous recombination-proficient ovarian cancer by suppressing CRY1 via PI3K/AKT pathway

Iida, Y., Yanaihara, N., Yoshino, Y., Saito, M., Saito, R., Tabata, J., Kawabata, A., Takenaka, M., Chiba, N., & Okamoto, A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1302850 · Cited by 15 · see citing works

Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer

Kulkarni, S., Gajjar, K. B., & Madhusudan, S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1414112 · Cited by 15 · see citing works

Strategies for the prevention or reversal of PARP inhibitor resistance

Mitri, Z. I., Goodyear, S. M., & Mills, G. B. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2393251 · Cited by 15 · see citing works

Vitamin D Modulates the Response of Patient-Derived Metastatic Melanoma Cells to Anticancer Drugs

Piotrowska, A., Zaucha, R., Król, O., & Zmijewski, M. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098037 · Cited by 15 · see citing works

LncRNA MIR4435-2HG drives cancer progression by modulating cell cycle regulators and mTOR signaling in stroma-enriched subtypes of urothelial carcinoma of the bladder

Pei, L., Yan, D., He, Q., Kong, J., Yang, M., Ruan, H., Lin, Q., Huang, L., Huang, J., Lin, T., et al. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00826-5 · Cited by 15 · see citing works

The Prognostic and Therapeutic Potential of DNA Damage Repair Pathway Alterations and Homologous Recombination Deficiency in Lung Cancer

Khaddour, K., Fernandez, M. F., Khabibov, M., Гарифуллин, А., Dressler, D., Topchu, I., Patel, J. D., Weinberg, F. D., & Boumber, Y. (2022) · Cancers · doi:10.3390/cancers14215305 · Cited by 14 · see citing works

The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer

Murphy, A. D., Morgan, R. D., Clamp, A. R., & Jayson, G. C. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01605-5 · Cited by 13 · see citing works

Novel benzofuran-conjugated indolin-2-ones as anticancer agents; design, synthesis, biological assessments, and molecular modeling insights

Eldehna, W. M., Tawfik, H. O., Nafie, M. S., Kamaly, O. M. A., El-Hamaky, A. A., Hassab, M. A. E., Elsayed, Z. M., Elnaggar, Y. S. R., Al-Karmalawy, A. A., di Giacomo, V., et al. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108494 · Cited by 13 · see citing works

The DNA damaging revolution

Çetin, B., Wabl, C. A., & Gümüşay, Ö. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103117 · Cited by 13 · see citing works

PARP inhibitor synthetic lethality in ATM biallelic mutant cancer cell lines is associated with BRCA1/2 and RAD51 downregulation

Muvaffak, A., & Coleman, K. G. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1380633 · Cited by 12 · see citing works

Repression of PFKFB3 sensitizes ovarian cancer to PARP inhibitors by impairing homologous recombination repair

Xiao, Y., Wu, Y., Wang, Q., Li, M., Deng, C., & Gu, X. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02056-8 · Cited by 12 · see citing works

Response to olaparib in metastatic lung adenocarcinoma with germline BRCA2 mutation: a case report

Wu, C., Fan, M., & Hu, Y. (2021) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001160 · Cited by 12 · see citing works

Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers

Liu, X., Ge, Z., Yang, F., Contreras, A., Lee, S., White, J. B., Lu, Y., Labrie, M., Arun, B., Moulder, S. L., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00427-9 · Cited by 12 · see citing works

Combined PARP inhibitors and small molecular inhibitors in solid tumor treatment (Review)

Jin, N. Y., Xia, Y., & Gao, Q. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5476 · Cited by 12 · see citing works

Harnessing the effects of hypoxia-like inhibition on homology-directed DNA repair

Altwerger, G. H., Ghazarian, M., & Glazer, P. M. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.11.007 · Cited by 13 · see citing works

Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?

Gourley, C., Miller, R. E., Hollis, R. L., & Ledermann, J. A. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000660 · Cited by 12 · see citing works

Current and future landscape of poly (ADP-ribose) polymerase inhibition resistance

Hinchcliff, E., Chelariu-Raicu, A., & Westin, S. N. (2020) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000678 · Cited by 12 · see citing works

Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints

Ivy, S. P., Kunos, C. A., Arnaldez, F. I., & Kohn, E. C. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1657403 · Cited by 11 · see citing works

Synergistic antitumor effect of liposomal-based formulations of olaparib and topotecan in primary epithelial ovarian cancer cells

Romaniuk-Drapała, A., Skupin-Mrugalska, P., Garbuzenko, O. B., Hatefi, A., & Minko, T. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03469-0 · Cited by 11 · see citing works

Strategic Combination Therapies for Ovarian Cancer

Li, X., Ng, A. S. N., Mak, V. C. Y., Chan, K. K. L., Cheung, A., & Cheung, L. W. T. (2020) · Current Cancer Drug Targets · doi:10.2174/1568009620666200511084007 · Cited by 11 · see citing works

Protein kinase inhibitors for the treatment of prostate cancer

Chau, V., Madan, R. A., & Aragon‐Ching, J. B. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1925250 · Cited by 11 · see citing works

Advances in predicting breast cancer driver mutations: Tools for precision oncology (Review)

Hao, W., Rajendran, B. K., Cui, T., Sun, J., Yingchun, Z., Palaniyandi, T., & Selvam, M. (2024) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2024.5447 · Cited by 10 · see citing works

Clinical application of PARP inhibitors and emerging strategies to overcome resistance: a pan-cancer perspective

Xiang, J., Li, J., Guo, Z., Wu, J., Ma, D., Xu, H., Shang, T., Pu, P., Cong, L., Zhou, R., et al. (2026) · Biomarker Research · doi:10.1186/s40364-026-00908-0 · Cited by 10 · see citing works

Therapeutic biomarkers in metastatic castration-resistant prostate cancer: does the state matter?

Slootbeek, P. H. J., Tolmeijer, S. H., Mehra, N., & Schalken, J. A. (2023) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2023.2266482 · Cited by 11 · see citing works

Efficacy and safety of VEGF/VEGFR inhibitors for platinum-resistant ovarian cancer: a systematic review and meta-analysis of randomized controlled trials

Huang, D., Ke, L., Cui, H., Su, L., & Sun, F. (2024) · BMC Women s Health · doi:10.1186/s12905-023-02879-y · Cited by 10 · see citing works

A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib

Liu, J. F., Xiong, N., Wenham, R. M., Hendrickson, A. E. W., Armstrong, D. K., Chan, N., O’Malley, D. M., Lee, J.-M., Penson, R. T., Cristea, M. C., et al. (2024) · Gynecologic Oncology · doi:10.1016/j.ygyno.2024.05.002 · Cited by 10 · see citing works

Anti-angiogenic therapy in ovarian cancer: current situation & prospects

Liu, Y., Luo, Y., Cai, M., Shen, P., Li, J., Chen, H., Bao, W., & Zhu, Y. (2021) · International Journal of Microbiology Research · doi:10.4103/ijmr.ijmr_1160_19 · Cited by 10 · see citing works

The impact of PARP inhibitors in the whole scenario of ovarian cancer management: A systematic review and network meta-analysis

Staropoli, N., Ciliberto, D., Luciano, F., Napoli, C., Costa, M., Rossini, G., Arbitrio, M., Labanca, C., Riillo, C., Giudice, T. D., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104229 · Cited by 9 · see citing works

Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition

Rackear, M., Quijano, E., Ianniello, Z., Colón-Ríos, D. A., Krysztofiak, A., Abdullah, R., Liu, Y., Rogers, F. A., Ludwig, D. L., Dwivedi, R., et al. (2024) · Oncotarget · doi:10.18632/oncotarget.28651 · Cited by 9 · see citing works

Mechanism of Cediranib–Olaparib Combo Revealed

(2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2019-064 · Cited by 1 · see citing works

Abstract 3718: Sensitization of human tumor cells to chemotherapy drugs by antisense downregulation of RAD51: Targeting DNA repair to induce synthetic lethality

Ferguson, P. J., Rytelewski, M., Vincent, M. D., & Koropatnick, J. D. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-3718 · Cited by 1 · see citing works

Analysis of homologous recombination DNA repair gene mutation status in patients with metastatic small cell lung cancer treated with cediranib and olaparib on NCI 9881 study.

Kim, J. W., Radke, M. R., Hafez, N., Soliman, H. H., Fu, S., Kato, S., Lara, P. N., Vaishampayan, U. N., Razak, A. R. A., Cardin, D. B., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.8563

Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors

Jdey, W., Thierry, S., Russo, C., Devun, F., Abo, M. A., Noguiez, P., Sun, J., Barillot, E., Zinovyev, A. Y., Kuperstein, I., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1193 · Cited by 42 · see citing works

Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation

Kim, J. W., Cardin, D. B., Vaishampayan, U. N., Kato, S., Grossman, S. R., Glazer, P. M., Shyr, Y., Ivy, S. P., & LoRusso, P. M. (2021) · The Oncologist · doi:10.1002/onco.13758 · Cited by 17 · see citing works